Ki-67 is a Strong Prognostic Marker of Non-small Cell Lung Cancer when Tissue Heterogeneity is Considered

Overview

Journal BMC Clin Pathol

Publisher Biomed Central

Date 2014 May 27

PMID 24860257

Citations 26

Authors

Kazuhiro Tabata

Tomonori Tanaka

Tomayoshi Hayashi

Takashi Hori

Sayuri Nunomura

Suguru Yonezawa

Junya Fukuoka

Affiliations

Soon will be listed here.

Abstract

Background: Ki-67 expression is a well-established prognostic marker in various cancers. However, Ki-67 expression is also known as being heterogeneous. We investigated the prognostic significance of Ki-67 from the view of staining heterogeneity by the technique of Spiral Array.

Methods: 100 cases of resected lung cancer from Toyama university hospital archive were collected. Spiral Array blocks were generated out of 100 cases using 100 μm thick paraffin sections. Four μm thick sections of the Array block were stained for Ki-67. Staining results in each reel were scored for areas with lowest (LS), highest (HS), and average (AS) expression, exclusively in the cancer cells. Heterogeneity score (HeS) was designed as the difference between HS and LS. The scores were divided into four grades (0-3). Clinical information was collected, and the prognostic significance of Ki-67 was analyzed.

Results: Pathological stage was available for 91 patients (43 stage IA, 22 stage IB, 2 stage IIA, 9 stage IIB, 13 stage IIIA, 1 stage IIIB, and 1 stage IV). The HS of Ki-67 score in non-small cell lung cancer was 3 in 17 cases, 2 in 27 cases, 1 in 28 cases, 0 in 21 cases, and 4 reels were lost. 78 cases had clinical follow up. 74 cases had all the information available and were analyzed for correlation between Ki-67 expression and survival. Cases with score 2 and 3 of HS and HeS showed significant poorer prognosis (both P < 0.001), whereas LS or AS did not show significance. The results were identical when analyzing adenocarcinoma and squamous cell carcinoma, separately. Cox multivariate analysis of Ki-67 showed that HS was an independent risk factor affecting overall survival.

Conclusions: Ki-67 is a strong prognostic marker for non-small cell lung cancer when the degree of highest staining frequency or heterogeneity is considered.

Citing Articles

Soft-tissue sarcoma: modified grading method improves the accuracy of preoperative MRI in predicting patient outcomes.

Li X, Hu Y, Xie Y, Huang B, Chen S, Tao H Eur Radiol. 2025; .

PMID: 39915321 DOI: 10.1007/s00330-025-11365-y.

Modeling lung adenocarcinoma metastases using patient-derived organoids.

Liu Y, Lankadasari M, Rosiene J, Johnson K, Zhou J, Bapat S Cell Rep Med. 2024; 5(10):101777.

PMID: 39413736 PMC: 11513837. DOI: 10.1016/j.xcrm.2024.101777.

Seed () Attenuates Chemically Induced Lung Carcinomas in Rats through Suppression of Proliferation and Angiogenesis.

Ali N, Elsayed G, Mohamed S, Abd Elkarim A, Aly M, Elgamal A Pharmaceuticals (Basel). 2024; 17(9).

PMID: 39338293 PMC: 11435337. DOI: 10.3390/ph17091129.

Effect of Sevoflurane on the Proliferation of A549 Lung Cancer Cells.

Yun S, Kim K, Shin K, Park H, Lee S, Shin Y Medicina (Kaunas). 2023; 59(3).

PMID: 36984614 PMC: 10054785. DOI: 10.3390/medicina59030613.

Dynamic monitoring of PD-L1 and Ki67 in circulating tumor cells of metastatic non-small cell lung cancer patients treated with pembrolizumab.

Spiliotaki M, Neophytou C, Vogazianos P, Stylianou I, Gregoriou G, Constantinou A Mol Oncol. 2022; 17(5):792-809.

PMID: 36177552 PMC: 10158784. DOI: 10.1002/1878-0261.13317.

References

Klimstra D, Modlin I, Coppola D, Lloyd R, Suster S . The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. 2010; 39(6):707-12. DOI: 10.1097/MPA.0b013e3181ec124e. View

Bergethon K, Shaw A, Ou S, Katayama R, Lovly C, McDonald N . ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012; 30(8):863-70. PMC: 3295572. DOI: 10.1200/JCO.2011.35.6345. View

Dowsett M, Nielsen T, AHern R, Bartlett J, Coombes R, Cuzick J . Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst. 2011; 103(22):1656-64. PMC: 3216967. DOI: 10.1093/jnci/djr393. View

Takano T, Fukui T, Ohe Y, Tsuta K, Yamamoto S, Nokihara H . EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan. J Clin Oncol. 2008; 26(34):5589-95. DOI: 10.1200/JCO.2008.16.7254. View

Inoue M, Takakuwa T, Minami M, Shiono H, Utsumi T, Kadota Y . Clinicopathologic factors influencing postoperative prognosis in patients with small-sized adenocarcinoma of the lung. J Thorac Cardiovasc Surg. 2008; 135(4):830-6. DOI: 10.1016/j.jtcvs.2007.10.034. View

Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin D . Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2011; 127(12):2893-917. DOI: 10.1002/ijc.25516. View

Terasaki H, Niki T, Matsuno Y, Yamada T, Maeshima A, Asamura H . Lung adenocarcinoma with mixed bronchioloalveolar and invasive components: clinicopathological features, subclassification by extent of invasive foci, and immunohistochemical characterization. Am J Surg Pathol. 2003; 27(7):937-51. DOI: 10.1097/00000478-200307000-00009. View

Couvelard A, Deschamps L, Ravaud P, Baron G, Sauvanet A, Hentic O . Heterogeneity of tumor prognostic markers: a reproducibility study applied to liver metastases of pancreatic endocrine tumors. Mod Pathol. 2008; 22(2):273-81. DOI: 10.1038/modpathol.2008.177. View

Miyake H, Muramaki M, Kurahashi T, Takenaka A, Fujisawa M . Expression of potential molecular markers in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. Urol Oncol. 2008; 28(2):145-51. DOI: 10.1016/j.urolonc.2008.08.001. View

10.

Komiya A, Kato T, Hori T, Fukuoka J, Yasuda K, Fuse H . Application of a new technique, spiral tissue microarrays constructed using needle biopsy specimens, to prostate cancer research. Int J Oncol. 2013; 44(1):195-202. DOI: 10.3892/ijo.2013.2173. View

11.

MacDonald C, Michael A, Colston K, Mansi J . Heterogeneity of immunostaining for tumour markers in non-small cell lung carcinoma. Eur J Cancer. 2004; 40(3):461-6. DOI: 10.1016/j.ejca.2003.10.019. View

12.

Fukuoka J, Hofer M, Hori T, Tanaka T, Ishizawa S, Nomoto K . Spiral array: a new high-throughput technology covers tissue heterogeneity. Arch Pathol Lab Med. 2012; 136(11):1377-84. DOI: 10.5858/arpa.2011-0393-OA. View

13.

Potts S, Krueger J, Landis N, Eberhard D, Young G, Schmechel S . Evaluating tumor heterogeneity in immunohistochemistry-stained breast cancer tissue. Lab Invest. 2012; 92(9):1342-57. DOI: 10.1038/labinvest.2012.91. View

14.

Tawfik K, Kimler B, Davis M, Fan F, Tawfik O . Ki-67 expression in axillary lymph node metastases in breast cancer is prognostically significant. Hum Pathol. 2012; 44(1):39-46. DOI: 10.1016/j.humpath.2012.05.007. View

15.

Haga Y, Hiroshima K, Iyoda A, Shibuya K, Shimamura F, Iizasa T . Ki-67 expression and prognosis for smokers with resected stage I non-small cell lung cancer. Ann Thorac Surg. 2003; 75(6):1727-32; discussion 1732-3. DOI: 10.1016/s0003-4975(03)00119-x. View

16.

Gerdes J, Lemke H, Baisch H, Wacker H, Schwab U, STEIN H . Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984; 133(4):1710-5. View

17.

Veronese S, Gambacorta M, Gottardi O, Scanzi F, Ferrari M, Lampertico P . Proliferation index as a prognostic marker in breast cancer. Cancer. 1993; 71(12):3926-31. DOI: 10.1002/1097-0142(19930615)71:12<3926::aid-cncr2820711221>3.0.co;2-2. View

18.

Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G . DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med. 2007; 356(8):800-8. DOI: 10.1056/NEJMoa065411. View

19.

Pfister C, Lacombe L, Vezina M, Moore L, Larue H, Tetu B . Prognostic value of the proliferative index determined by Ki-67 immunostaining in superficial bladder tumors. Hum Pathol. 1999; 30(11):1350-5. DOI: 10.1016/s0046-8177(99)90067-9. View

20.

Hommura F, Dosaka-Akita H, Mishina T, Nishi M, Kojima T, Hiroumi H . Prognostic significance of p27KIP1 protein and ki-67 growth fraction in non-small cell lung cancers. Clin Cancer Res. 2000; 6(10):4073-81. View